insights_auto
Miks on GIS tõusnud? 3,18%?
Uurige põhjalikumaltchevron_right
GIS:ETR
Gilead Sciences, Inc
133,64 €
arrow_upward
+3,18%(+4,12) 1 p
9. okt, 17:35:39 GMT +2 · EUR
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse GIS põhistatistika genereerimine…
Ava
131,64 €
Kõrge
133,64 €
Madal
130,76 €
Turu kapit.
187,44 mld
Keskm. maht
683,00
Maht
3,01 tuh
52 näd kõrgeim
136,24 €
52 näd madalaim
98,96 €
Töötajate arv
17 tuh
Ava
131,64 €
Kõrge
133,64 €
Madal
130,76 €
Turu kapit.
187,44 mld
Keskm. maht
683,00
Maht
3,01 tuh
52 näd kõrgeim
136,24 €
52 näd madalaim
98,96 €
Töötajate arv
17 tuh
Uudised
Veebiallikatest ja uudistepartneritelt
AD HOC NEWS
·
10 tunni eest
Gilead Sciences stock trades 0.17 percent above its Xetra close of EUR 134.84
Trefis
·
18 tunni eest
Why Is Everyone Ignoring Gilead Stock’s High Cash Yield?
AD HOC NEWS
·
1 päeva eest
RBC raises target for Gilead Sciences stock to USD 126.00
Yahoo Finance
·
2 päeva eest
Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD)
Profiil
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Teave üksuse Gilead Sciences, Inc kohta
TegevjuhtDaniel O'Day
Töötajad17 tuh
Asutatud22. juuni 1987
PeakontoridFoster City, California, Ameerika Ühendriigid
Sektor-
Veebisaitgilead.com